S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
NASDAQ:CRSP

CRISPR Therapeutics - CRSP Stock Forecast, Price & News

$68.60
-3.55 (-4.92%)
(As of 08/19/2022 04:32 PM ET)
Add
Compare
Today's Range
$68.21
$71.77
50-Day Range
$55.27
$83.78
52-Week Range
$42.51
$129.50
Volume
1.44 million shs
Average Volume
1.69 million shs
Market Capitalization
$5.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$112.33

CRISPR Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
63.8% Upside
$112.33 Price Target
Short Interest
Bearish
15.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.01mentions of CRISPR Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$3.44 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($9.23) to ($7.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

494th out of 1,119 stocks

Biological Products, Except Diagnostic Industry

73rd out of 178 stocks

CRSP stock logo

About CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Analyst Ratings Changes

Several equities analysts have recently issued reports on CRSP shares. Chardan Capital decreased their price target on CRISPR Therapeutics from $164.00 to $154.00 and set a "buy" rating on the stock in a research note on Tuesday, August 9th. Needham & Company LLC dropped their target price on CRISPR Therapeutics from $170.00 to $122.00 in a research report on Friday, May 13th. BMO Capital Markets initiated coverage on CRISPR Therapeutics in a research note on Thursday, June 16th. They issued an "outperform" rating and a $98.00 target price on the stock. Oppenheimer reduced their price objective on CRISPR Therapeutics from $150.00 to $122.00 and set an "outperform" rating on the stock in a research note on Thursday, June 23rd. Finally, Credit Suisse Group increased their target price on shares of CRISPR Therapeutics from $74.00 to $90.00 and gave the stock a "neutral" rating in a report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $112.33.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ:CRSP opened at $72.15 on Friday. The company has a market capitalization of $5.63 billion, a PE ratio of -8.77 and a beta of 1.93. CRISPR Therapeutics has a 52 week low of $42.51 and a 52 week high of $129.50. The company has a 50 day moving average price of $72.90 and a two-hundred day moving average price of $64.03.

CRISPR Therapeutics (NASDAQ:CRSP - Get Rating) last announced its quarterly earnings results on Monday, August 8th. The company reported ($2.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.21) by ($0.19). The business had revenue of $0.20 million during the quarter, compared to analyst estimates of $2.20 million. CRISPR Therapeutics had a negative net margin of 4,274.02% and a negative return on equity of 27.40%. The company's revenue was down 100.0% compared to the same quarter last year. During the same quarter last year, the company posted $9.44 earnings per share. On average, sell-side analysts forecast that CRISPR Therapeutics will post -9.23 earnings per share for the current year.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 25,000 shares of the stock in a transaction on Wednesday, June 29th. The stock was sold at an average price of $61.59, for a total value of $1,539,750.00. Following the completion of the sale, the chief executive officer now owns 290,279 shares in the company, valued at approximately $17,878,283.61. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.30% of the stock is owned by company insiders.

Receive CRSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRSP Stock News Headlines

MarketBeat: Week in Review 8/1 - 8/5 (CRSP)
The hot jobs report is dispelling any notion that interest rates will level off. But the market moves on and here are some of the stocks and stories to follow.
Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
This article reviews the current state of affairs for CRISPR Therapeutics so you can decide if the gene editing company is worth a speculative investment
Is the US Military Secretly Under Chinese Control?
Alarmingly, the answer may be "yes". Communist China now controls 80% of the lithium that powers most US military vehicles and equipment. The threat level is so high that the White House recently declared a state of emergency on lithium...
The Coming Copper Bull Run
Copper prices have nearly doubled since last year -- driven by the explosive growth in electric vehicles and soaring demand for green-powered electricity. But copper demand far outpaces supply. Multinational investment banks are predicting a 50% to 100% rise in copper prices by 2025. And this "backdoor" play may be a move to consider.
Cathie Wood Dumped These 7 Stocks in July
See More Headlines
Receive CRSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRSP Company Calendar

Last Earnings
8/08/2022
Today
8/19/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRSP
Fax
N/A
Employees
473
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$112.33
High Stock Price Forecast
$220.00
Low Stock Price Forecast
$46.00
Forecasted Upside/Downside
+63.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
16 Analysts

Profitability

Net Income
$377.66 million
Net Margins
-4,274.02%
Pretax Margin
-4,227.61%

Debt

Sales & Book Value

Annual Sales
$914.96 million
Cash Flow
$5.12 per share
Book Value
$26.80 per share

Miscellaneous

Free Float
73,875,000
Market Cap
$5.35 billion
Optionable
Optionable
Beta
1.93

Key Executives

  • Dr. Rodger Novak M.D. (Age 55)
    Founder, Chairman & Pres
  • Dr. Samarth  KulkarniDr. Samarth Kulkarni (Age 43)
    CEO & Director
    Comp: $1.18M
  • Dr. Lawrence Otto Klein Ph.D.Dr. Lawrence Otto Klein Ph.D. (Age 40)
    Chief Operating Officer
    Comp: $675k
  • Mr. James R. KasingerMr. James R. Kasinger (Age 50)
    Gen. Counsel & Sec.
    Comp: $648.93k
  • Mr. Shaun Foy
    Founder
  • Dr. Emmanuelle Marie Charpentier
    Co-Founder & Scientific Advisory Board Member
  • Dr. Craig C. Mello Ph.D.
    Scientific Founder & Advisory Board Member
  • Dr. Chad Cowan Ph.D.
    Scientific Founder
  • Dr. Matthew Porteus M.D. (Age 56)
    Ph.D., Scientific Founder & Advisory Board Member
  • Dr. Daniel G. Anderson Ph.D.
    Scientific Founder & Advisory Board Member













CRSP Stock - Frequently Asked Questions

Should I buy or sell CRISPR Therapeutics stock right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last twelve months. There are currently 7 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRSP shares.
View CRSP analyst ratings
or view top-rated stocks.

What is CRISPR Therapeutics' stock price forecast for 2022?

16 Wall Street analysts have issued 1-year price targets for CRISPR Therapeutics' shares. Their CRSP share price forecasts range from $46.00 to $220.00. On average, they anticipate the company's stock price to reach $112.33 in the next twelve months. This suggests a possible upside of 55.7% from the stock's current price.
View analysts price targets for CRSP
or view top-rated stocks among Wall Street analysts.

How have CRSP shares performed in 2022?

CRISPR Therapeutics' stock was trading at $75.78 at the beginning of the year. Since then, CRSP stock has decreased by 4.8% and is now trading at $72.15.
View the best growth stocks for 2022 here
.

When is CRISPR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our CRSP earnings forecast
.

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) posted its earnings results on Monday, August, 8th. The company reported ($2.40) EPS for the quarter, missing the consensus estimate of ($2.21) by $0.19. The firm earned $0.20 million during the quarter, compared to the consensus estimate of $2.20 million. CRISPR Therapeutics had a negative trailing twelve-month return on equity of 27.40% and a negative net margin of 4,274.02%. The business's revenue was down 100.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $9.44 earnings per share.

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (5.92%), Nikko Asset Management Americas Inc. (5.92%), Price T Rowe Associates Inc. MD (3.86%), FMR LLC (2.08%), State Street Corp (2.01%) and Loomis Sayles & Co. L P (1.80%). Insiders that own company stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Tony W Ho and Tony W Ho.
View institutional ownership trends
.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $72.15.

How much money does CRISPR Therapeutics make?

CRISPR Therapeutics (NASDAQ:CRSP) has a market capitalization of $5.63 billion and generates $914.96 million in revenue each year. The company earns $377.66 million in net income (profit) each year or ($8.23) on an earnings per share basis.

How many employees does CRISPR Therapeutics have?

The company employs 473 workers across the globe.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The official website for the company is www.crisprtx.com. The company can be reached via phone at (141) 561-3277 or via email at susan.kim@crisprtx.com.

This page (NASDAQ:CRSP) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.